Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 6/20 | 0.51 |
| ▸ | BRAF | P15056 | 11/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | SIK1 | P57059 | 2/20 | 0.37 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.37 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.37 |
| ▸ | GAK | O14976 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.37 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.37 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.37 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | EPHB1 | P54762 | 1/20 | 0.37 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22200304 | 0.89 | ERN1 (0.47) | ERN1BRAFRAF1SIK1SIK2 | |
| SCHEMBL25034109 | 0.89 | BRAF (0.49) | ERN1BRAFALOX5APFEN1 | |
| SCHEMBL29354829 | 0.89 | ERN1 (0.46) | ERN1BRAFALOX5APFEN1 | |
| SCHEMBL29352926 | 0.89 | ERN1 (0.46) | ERN1BRAFALOX5APFEN1 | |
| SCHEMBL22190865 | 0.89 | ERN1 (0.46) | ERN1BRAFALOX5APFEN1 | |
| SCHEMBL22190791 | 0.89 | ERN1 (0.46) | ERN1BRAFALOX5APFEN1 | |
| SCHEMBL22191294 | 0.87 | ERN1 (0.59) | ERN1BRAFMAPK8 | |
| SCHEMBL29356309 | 0.87 | ERN1 (0.59) | ERN1BRAFMAPK8 | |
| SCHEMBL22200524 | 0.87 | ERN1 (0.58) | ERN1BRAFMAPK8 | |
| SCHEMBL22190977 | 0.86 | ERN1 (0.57) | ERN1BRAFMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | PARAZA PHARMA, INC. (CA) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047209-A1 | PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AND METHODS OF USE | TYMP, TYMS, DPYD | ERN1 3167/4885BRAF 563/4885RAF1 2273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.